A recent clinical case report [27] from an investigator-initiated study claimed that mifepristone as a single agent prevented the progression of stage IV PDL1+ non-small-cell lung cancer in a patient who failed to respond to prior chemotherapy and PD1-blocking Ab (nivolumab). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.